ASCENTAGE PHARMA EUROPE LIMITED

Ascentage Pharma Europe Limited is an integrated global biopharmaceutical company dedicated to discovering, developing and commercialising first‑ and best‑in‑class therapies that restore the normal cell‑death process in cancer and other serious diseases. Drawing on more than two decades of expertise, the firm has built a proprietary drug‑discovery platform that tackles some of the most challenging targets, making it the only company worldwide with active clinical programmes aimed at all three known classes of key apoptosis regulators.

The company’s pipeline includes novel agents such as Olverembatinib for treatment‑resistant cancers (targeting BCR‑ABL/KIT kinases), Lisaftoclax for leukaemias and related blood cancers (BCL‑2 inhibition), Pelcitoclax for solid tumours and blood cancers (dual BCL‑2/XL inhibition) and Alrizomadlin for solid tumours and blood cancers (MDM2‑p53 pathway). To date, Ascentage has completed or is running eleven international registrational trials, two of which are FDA‑regulated, underscoring its commitment to bringing innovative, apoptosis‑focused therapies to patients worldwide.

In line with its growth strategy, Ascentage actively pursues co‑development and co‑promotion partnerships, seeking collaborators whose portfolios complement the unique mechanisms of action of its candidates. This collaborative approach accelerates the delivery of life‑changing treatments to the global market.